Liminal BioSciences Inc. LMNL
Set alert
8.50 +8.50 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 26.04M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -0.92
- Beta
- 29.84
- Short ratio
- 4.03
- Inst. own
- 0.59%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 8, 2023
- 50-d avg
- 6.68
- 200-d avg
- 5.28
- 1y target
- 7.53
2Y chart
Events in this range
- Aug 9, 2022Earnings: —; estimate 0; surprise —%
- Nov 9, 2022Earnings: —; estimate 0; surprise —%
- Feb 1, 2023Split: 1 for 10
- Mar 15, 2023Earnings: —; estimate 0; surprise —%
- May 9, 2023Earnings: —; estimate 0; surprise —%
- Aug 8, 2023Earnings: —; estimate 0; surprise —%
Signals (75)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Sep 13, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 2, 2023 | 3 years ago |
| SMA: Bullish | Jul 12, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 12, 2023 | 3 years ago |
| RSI: Overbought | Jul 12, 2023 | 3 years ago |
| RSI: Oversold | Jul 11, 2023 | 3 years ago |
| SMA: Bearish | Jun 22, 2023 | 3 years ago |
| SMA: Bullish | Jun 14, 2023 | 3 years ago |
| SMA: Bearish | Jun 13, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 28, 2023 | 3 years ago |
| RSI: Overbought | Apr 18, 2023 | 3 years ago |
| SMA: Bullish | Apr 5, 2023 | 3 years ago |
| SMA: Bullish | Apr 5, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 5, 2023 | 3 years ago |
| RSI: Overbought | Apr 5, 2023 | 3 years ago |
| RSI: Oversold | Apr 4, 2023 | 3 years ago |
| SMA: Bearish | Mar 15, 2023 | 3 years ago |
| SMA: Bearish | Mar 15, 2023 | 3 years ago |
| RSI: Oversold | Mar 15, 2023 | 3 years ago |
| RSI: Overbought | Feb 28, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 21, 2023 | 3 years ago |
| RSI: Overbought | Feb 3, 2023 | 3 years ago |
| SMA: Bullish | Feb 1, 2023 | 3 years ago |
| RSI: Overbought | Feb 1, 2023 | 3 years ago |
| SMA: Bullish | Jan 30, 2023 | 3 years ago |
| SMA: Bearish | Jan 27, 2023 | 3 years ago |
| SMA: Bullish | Jan 26, 2023 | 3 years ago |
| SMA: Bearish | Jan 25, 2023 | 3 years ago |
| SMA: Bullish | Jan 23, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 10, 2023 | 3 years ago |
| MACD: Sell Signal | Dec 22, 2022 | 3 years ago |
| RSI: Oversold | Dec 22, 2022 | 3 years ago |
| MACD: Buy Signal | Dec 14, 2022 | 3 years ago |
| SMA: Bearish | Nov 18, 2022 | 3 years ago |
| SMA: Bullish | Nov 17, 2022 | 3 years ago |
| SMA: Bearish | Nov 10, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 3, 2022 | 3 years ago |
| SMA: Bullish | Oct 13, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 6, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 29, 2022 | 4 years ago |
| SMA: Bearish | Sep 28, 2022 | 4 years ago |
| SMA: Bullish | Sep 27, 2022 | 4 years ago |
| MACD: Buy Signal | Sep 27, 2022 | 4 years ago |
| SMA: Bearish | Sep 2, 2022 | 4 years ago |
| SMA: Bullish | Sep 1, 2022 | 4 years ago |
| SMA: Bearish | Aug 30, 2022 | 4 years ago |
| SMA: Bullish | Aug 29, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 29, 2022 | 4 years ago |
| SMA: Bearish | Aug 26, 2022 | 4 years ago |
| SMA: Bullish | Aug 11, 2022 | 4 years ago |
| SMA: Bearish | Aug 10, 2022 | 4 years ago |
| SMA: Bullish | Aug 8, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 8, 2022 | 4 years ago |
| SMA: Bearish | Jul 22, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 22, 2022 | 4 years ago |
| SMA: Bullish | Jul 5, 2022 | 4 years ago |
| RSI: Oversold | Jun 27, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 21, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 17, 2022 | 4 years ago |
| RSI: Oversold | Jun 13, 2022 | 4 years ago |
| MACD: Buy Signal | May 31, 2022 | 4 years ago |
| RSI: Oversold | May 23, 2022 | 4 years ago |
| RSI: Oversold | May 18, 2022 | 4 years ago |
| RSI: Oversold | May 6, 2022 | 4 years ago |
| SMA: Bearish | Apr 19, 2022 | 4 years ago |
| SMA: Bullish | Apr 18, 2022 | 4 years ago |
| SMA: Bearish | Apr 14, 2022 | 4 years ago |
| SMA: Bullish | Apr 13, 2022 | 4 years ago |
| SMA: Bearish | Apr 11, 2022 | 4 years ago |
| SMA: Bullish | Apr 8, 2022 | 4 years ago |
| SMA: Bearish | Apr 7, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 6, 2022 | 4 years ago |
| SMA: Bullish | Mar 22, 2022 | 4 years ago |
| MACD: Buy Signal | Feb 3, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 24, 2022 | 4 years ago |
Key statistics
- Market cap
- 26.04M
- Enterprise value
- 273.17K
- Trailing P/E
- 0.00
- Forward P/E
- -0.92
- PEG ratio
- 0.00
- Price / sales
- 48.50
- Price / book
- 0.90
- EPS (TTM)
- -8.83
- Beta
- 29.84
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 702.61%
- Revenue (TTM)
- 537.00K
- Revenue growth
- 0.00%
- Free cash flow
- -25.90M
- Total cash
- 26.94M
- Total debt
- 1.36M
- Return on equity
- -96.58%
- Shares outstanding
- 3.10M
- Short % of float
- 2.57%
- 50-day average
- 6.68
- 200-day average
- 5.28
Analyst view
Consensus: hold
Hold
Price target (mean) 7.53
Next earnings
Nov 8, 2023
Expected Nov 8, 2023. Consensus EPS estimate 0.00.
Financials — quick view
LMNL Revenue — quarterly 112.00K
LMNL Net income — quarterly -9.14M
LMNL EPS — quarterly -2.94
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 8, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 9, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 15, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 9, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 9, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 24, 2021 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 2, 2021 | Piper Sandler | down | Overweight | Neutral |
| Feb 18, 2021 | HC Wainwright & Co. | init | — | Buy |
| Dec 21, 2020 | Piper Sandler | init | — | Overweight |
About Liminal BioSciences Inc.
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- liminalbiosciences.com
News
- LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP
- LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP
- LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP
- LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR
- LIMINAL BIOSCIENCES OBTAINS INTERIM ORDER FOR PROPOSED ARRANGEMENT WITH STRUCTURED ALPHA LP
- Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder
- Liminal BioSciences stock rockets on take-private deal with a fund managed by Thomvest Asset Management
- Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LP
- Why SeaChange International Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
- Why Kura Sushi Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Your note
Sign in to keep a note on LMNL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Best (Simon Geoffrey) | Director of Issuer | Acquisition or disposition in the public market | Mar 23, 2022 | 0 |
| Iskra, Marie | Senior Officer of Issuer | Acquisition or disposition in the public market | Sep 11, 2022 | 0 |
| Wach (Timothy Steven) | Director of Issuer | Acquisition or disposition in the public market | Mar 21, 2022 | 200 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Susquehanna International Group, LLP | 0.46% | 14,133 | 118.58K | Mar 30, 2023 |
| National Bank of Canada/FI | 0.32% | 9,853 | 82.67K | Mar 30, 2023 |
| Estabrook Capital Management | 0.02% | 500 | 4.20K | Mar 30, 2023 |
| Royal Bank of Canada | 0.02% | 502 | 4.21K | Mar 30, 2023 |
| UBS Group AG | 0.00% | 48 | 402 | Mar 30, 2023 |
| Tanaka Capital Management Inc | 0.00% | 1 | 8 | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.07% | 2,273 | 19.07K | Feb 27, 2023 |